ACADIA Pharmaceuticals (NASDAQ:ACAD) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.
Risk and Volatility
ACADIA Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.
Earnings and Valuation
This table compares ACADIA Pharmaceuticals and BeiGene's revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
ACADIA Pharmaceuticals | $339.08 million | 22.39 | $-235,260,000.00 | ($1.60) | -29.65 |
BeiGene | $428.21 million | 65.06 | $-948,630,000.00 | ($15.80) | -19.28 |
ACADIA Pharmaceuticals has higher earnings, but lower revenue than BeiGene. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 9.0% of BeiGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for ACADIA Pharmaceuticals and BeiGene, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
ACADIA Pharmaceuticals | 0 | 1 | 14 | 1 | 3.00 |
BeiGene | 2 | 2 | 4 | 0 | 2.25 |
ACADIA Pharmaceuticals presently has a consensus price target of $62.2667, indicating a potential upside of 31.25%. BeiGene has a consensus price target of $310.00, indicating a potential upside of 1.79%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than BeiGene.
Profitability
This table compares ACADIA Pharmaceuticals and BeiGene's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
ACADIA Pharmaceuticals | -63.92% | -40.35% | -34.72% |
BeiGene | -569.22% | -56.81% | -39.93% |
Summary
ACADIA Pharmaceuticals beats BeiGene on 12 of the 15 factors compared between the two stocks.